ArticleJournal of psychopharmacology (Oxford, England)2021
Mice lacking melatonin MT2 receptors exhibit attentional deficits, anxiety and enhanced social interaction.
Article in Journal of psychopharmacology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Review
- Degrading stimuli by reducing image resolution impairs performance in a rodent continuous performance test.Behavioural processes · 2023Article
- Age-Related Effects of Exogenous Melatonin on Anxiety-like Behavior in C57/B6J Mice.Biomedicines · 2023Article
- Neonatal loss of FGFR2 in astroglial cells affects locomotion, sociability, working memory, and glia-neuron interactions in mice.Translational psychiatry · 2023Article
- The relationship between anesthesia and melatonin: a review.Frontiers in pharmacology · 2023Review
- Melatonin as a Potential Approach to Anxiety Treatment.International journal of molecular sciences · 2022Review
- Systematic review reveals sexually antagonistic knockouts in model organisms.Ecology and evolution · 2022Review
- Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression.Neurochemical research · 2022Review
- Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.Therapeutic advances in psychopharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAside from regulating circadian rhythms, melatonin also affects cognitive processes, such as alertness, and modulates the brain circuitry underlying psychiatric diseases, such as depression, schizophrenia and bipolar disorder, via mechanisms that are not fully clear. In particular, while melatonin MT1 receptors are thought primarily to mediate the circadian effects of the hormone, the contribution of the MT2 receptor to melatonin actions remains enigmatic.
aimsTo characterise the contribution of MT2 receptors to melatonin's effects on cognition and anxiety/sociability.
methodsMice with a genetic deletion of the MT2 receptor, encoded by the
results
conclusionsThe results confirm that the MT2 receptor plays a role in cognition and also modulates anxiety and social interactions. These data provide new insights into the functions of endogenous melatonin and will inform future drug development strategies focussed on the MT2 receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.